EUVIMEDOpdag EUVIMED
Open access · CC BY 4.0

Effects of GLP ‐1 Receptor Agonists on Paediatric Population in a Real World Setting

A G Barajas, Charles A Gagnon-Vargas, Jessica A Schmitt iD

Endocrinology, Diabetes & Metabolism · 2025

DOI: 10.1002/edm2.70053 ↗

At a glance

Journal article in Endocrinology, Diabetes & Metabolism, 2025. Written by A G Barajas and 2 co-authors. Institution: University of Alabama at Birmingham Marnix E. Heersink School of Medicine, Birmingham, Alabama, USA. Major MEDLINE topics: Diabetes Mellitus, Type 2, Glucagon-Like Peptide-1 Receptor Agonists, Hypoglycemic Agents. Cited 1 times so far (Crossref); 23 references. The full text is freely available (open access, CC BY 4.0). Funded by: NCATS NIH HHS, NIH HHS, National Institutes of Health.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Objective

Incidence of type 2 diabetes mellitus (T2DM) and obesity is increasing in children. We aimed to observe the metabolic health effects of glucagon‐like peptide 1 (GLP‐1) receptor agonists in paediatric patients with T2DM in a real‐world setting.

Methods

A retrospective chart review of patients aged 0 to 18 years with T2DM who were started on a GLP‐1 receptor agonist between August 2019 and August 2023 and followed for up to 24 months was included in this study.

Results

321 patients were included in the analysis. After 12 months of treatment with a GLP‐1 receptor agonist, haemoglobin A1c (HbA1c) was reduced by −1.04% ± 2.3% ( p < 0.001). At 24 months, HbA1c was similar to baseline (8.3% ± 2.5% vs. 7.9% ± 2.5%, p = 0.24). There was a significant ( p < 0.05) decrease in the use of metformin, basal insulin, and bolus insulin at one year which was sustained at the two‐year follow‐up for metformin ( p = 0.002). Overall, there was no significant change in BMI nor other metabolic parameters while undergoing treatment with a GLP‐1 receptor agonist.

Conclusion

Paediatric patients with T2DM using GLP‐1 receptor agonists experienced a significant decrease in HbA1c after 12 months of use, which was not sustained at 24 months. However, patients had a reduction in insulin and metformin use at 12 months. No significant impact was appreciated on BMI or other metabolic variables.

Subjects

MeSH terms (MEDLINE)

Diabetes Mellitus, Type 2Glucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsHumansChildRetrospective StudiesFemaleAdolescentMaleChild, PreschoolInfantGlycated HemoglobinInfant, NewbornBlood GlucoseMetformin

Author keywords

adolescentdiabetes mellitusdrug utilisationglucagon‐like peptide‐1 receptor agoniststype 2

Substances

Glucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsGlycated Hemoglobinhemoglobin A1c protein, humanBlood GlucoseMetformin

Authors and institutions

  • University of Alabama at Birmingham Marnix E. Heersink School of Medicine, Birmingham, Alabama, USA.
  • Division of Pediatric Endocrinology and Diabetes, Department of Pediatrics, University of Alabama at Birmingham Marnix E. Heersink School of Medicine, Birmingham, Alabama, USA.

ORCID profiles: Jessica A Schmitt

Funding

  • NCATS NIH HHS
  • NIH HHS
  • National Institutes of Health

Cite

APA

Barajas, A. G., Gagnon-Vargas, C. A., & Schmitt, J. A. (2025). Effects of GLP ‐1 Receptor Agonists on Paediatric Population in a Real World Setting. Endocrinology, Diabetes & Metabolism. https://doi.org/10.1002/edm2.70053

Vancouver

Barajas AG, Gagnon-Vargas CA, Schmitt JA. Effects of GLP ‐1 Receptor Agonists on Paediatric Population in a Real World Setting. Endocrinology, Diabetes & Metabolism. 2025. doi:10.1002/edm2.70053

BibTeX
@article{Barajas2025,
  author = {Barajas, A G and Gagnon-Vargas, Charles A and Schmitt, Jessica A},
  title = {Effects of GLP ‐1 Receptor Agonists on Paediatric Population in a Real World Setting},
  journal = {Endocrinology, Diabetes & Metabolism},
  year = {2025},
  doi = {10.1002/edm2.70053}
}
Start for free →